Overcome bottlenecks in viral vector manufacturing

When you develop an AAV therapeutic, you need to assess many key parameters, or Critical Quality Attributes (CQAs), in order to track progress and, ultimately, get your therapeutic approved. As part

Optimizing your vectors for gene therapy is a daunting task. When developing and optimizing AAVs, concerns such as serotype, storage stability, expression method, and genetic fill level must be addres

New advances in gene therapy have triggered a resurgence of interest in the field. Though gene therapy offers exciting potential for the treatment of both monogenic disorders as well as more genetical

Gene therapy—a type of DNA-based medicine that utilizes a virus to insert a healthy gene into cells to replace a mutated, disease-causing variant has emerged as one of the most promising medical treat

Gene therapy promises to treat and potentially cure a disease by correcting its underlying genetic cause. While gene therapies that utilize AAV vectors have shown encouraging results —including a few